Free Trial
OTCMKTS:MDIT

CytoCore (MDIT) Stock Price, News & Analysis

$0.0001 0.00 (0.00%)
As of 10/5/2026 09:30 AM Eastern

About CytoCore Stock (OTCMKTS:MDIT)

Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
▼
$0.0001
Volume
2,026 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CytoCore, Inc. is a medical technology company focused on diagnostic products for cancer detection. The company has been associated with the development of automated systems used in cytology and tissue-processing workflows, with the goal of helping laboratories prepare and evaluate patient specimens.

Its product activities have included the CytoCore platform and related equipment or consumables intended to support the preparation of cellular samples for microscopic examination. These types of systems are designed for use by clinical laboratories and other healthcare providers involved in cancer screening and diagnosis.

Publicly available information about CytoCore’s current operations, geographic reach, product commercialization and leadership is limited. The company has historically been identified in connection with the over-the-counter symbol MDIT and earlier operations under the Medite Cancer Diagnostics name.

AI Generated. May Contain Errors.

Receive MDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoCore and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDIT Stock News Headlines

MDIT Medite Cancer Diagnostics, Inc.
Medite Cancer Diagnostics, Inc. (MDIT)
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Headlines

MDIT Stock Analysis - Frequently Asked Questions

CytoCore's stock was trading at $0.0001 at the start of the year. Since then, MDIT stock has increased by 0.0% and is now trading at $0.0001.

Shares of MDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoCore investors own include Cracker Barrel Old Country Store (CBRL), Banyan Gold (BYN), Blackstone Mortgage Trust (BXMT), Invesco BulletShares 2020 Corporate Bond ETF (BSCK), Bank of Marin Bancorp (BMRC) and BlackRock (BLK).

Company Calendar

Today
10/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
OTCMKTS:MDIT
CIK
75439
Employees
71
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
111.68
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:MDIT) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners